The Importance of Poly(ethylene glycol) Alternatives for Overcoming PEG Immunogenicity in Drug Delivery and Bioconjugation
Open accessThe DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Abstract
Poly(ethylene glycol) (PEG) is widely used as a gold standard in bioconjugation and nanomedicine to prolong blood circulation time and improve drug efficacy. The conjugation of PEG to proteins, peptides, oligonucleotides (DNA, small interfering RNA (siRNA), microRNA (miRNA)) and nanoparticles is a well-established technique known as PEGylation, with PEGylated products have been using in clinics for the last few decades. However, it is increasingly recognized that treating patients with PEGylated drugs can lead to the formation of antibodies that specifically recognize and bind to PEG (i.e., anti-PEG antibodies). Anti-PEG antibodies are also found in patients who have never been treated with PEGylated drugs but have consumed products containing PEG. Consequently, treating patients who have acquired anti-PEG antibodies with PEGylated drugs results in accelerated blood clearance, low drug efficacy, hypersensitivity, and, in some cases, life-threatening side effects. In this succinct review, we collate recent literature to draw the attention of polymer chemists to the issue of PEG immunogenicity in drug delivery and bioconjugation, thereby highlighting the importance of developing alternative polymers to replace PEG. Several promising yet imperfect alternatives to PEG are also discussed. To achieve asatisfactory alternative, further joint efforts of polymer chemists and scientists in related fields are urgently needed to design, synthesize and evaluate new alternatives to PEG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Anti-PEG IgM production as a function of time interval was tested in sera of rats intravenously injected with PEGylated liposomal gambogenic acid (PEG-GEA-L) at 1.500 mg/kg (a) [57]. Mice were treated with PEGylated liposomes of 1 μmol/kg, and the production of anti-PEG IgM in mouse sera was determined as a function of time (b) [58]. The effect of PEG-GEA-L doses on anti-PEG IgM production was recorded on the fifth day after the first injection. Rats were treated with low (1.125 mg/kg), medium (1.500 mg/kg), and high (1.875 mg/kg) dosages. ELISA was utilized to determine anti-PEG IgM (c). Anti-PEG IgM in organ tissues of rats that were intravenously injected with various PEG-GEA-L doses (d). Used with permission from [57]. (* p < 0.05, ** p < 0.01).](https://figures.cochat.ai/paper-figures/7f992d6c8db34717873a1a30c4da9e3e/the-importance-of-poly-ethylene-glycol-alternatives-for-overcoming-peg-figure-3.jpg)
![Figure 4 Production of anti-PEG IgM in the serum of mice injected PEGylated liposomes (PL) with various functional groups were determined by ELISA on the fifth day after administration. The lowest immunogenicity was exhibited by PL–OH (a). C3 binding in the serum of mice injected P–OCH3 and PL–OH on the fifth day, with non-treated mice as the control sample. Sera were diluted with a gelatin veronal buffer with Mg++ and Ca++ (GVB++) buffer (b) and an Mg2+/ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA) buffer (c). Mice treated with PL–OH demonstrated the highest compliment activation, driving the ABC phenomenon (d). Used with permission from the European Journal of Pharmaceutics and Biopharmaceutics [65]. Production of anti-PEG IgM rat sera against PEGylated emulsions (DE) with various functional groups seven days post-administration (e). Used with permission from the European Journal of Pharmaceutics and Biopharmaceutics [66]. (* p < 0.05, ** p < 0.01, *** p < 0.001).](https://figures.cochat.ai/paper-figures/334fab17dd8d42068469652d228b7ccc/the-importance-of-poly-ethylene-glycol-alternatives-for-overcoming-peg-figure-4.jpg)



![Figure 8 Chemical structure of the zwitterionic carboxybetaine functionalized polypeptide (PepCB) [79] (a). The preparation of poly(2-methacryloyloxyethyl phosphorylcholine)/poly(β-amino ester) (PMPC/PAE) mixed shell micelles (MSMs) with pH-sensitive behavior: MSMs were in zwitterionic state at a physiological blood pH (7.4) and in a cationic form within the tumor microenvironment (pH 6.5) (b).](https://figures.cochat.ai/paper-figures/52e563c21690478d8f338572002a504f/the-importance-of-poly-ethylene-glycol-alternatives-for-overcoming-peg-figure-8.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, these chemical modifications can potentially decrease transduction efficiency, lower production yield, alter biodistribution of AAV vectors, and result in anti-polymer antibody formation [198, 199].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [199]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200902672 · Cited by 3,533 · cited 3×
“However, the repeated administration of these polymers and/or NP-polymer conjugates may still trigger the production of anti-polymer antibodies, and further studies are needed to fully elucidate their immunogenic profiles [75,76].”
BackgroundPEGylation, successful approach to drug delivery
Veronese, F. M., & Pasut, G. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03575-0 · Cited by 2,339
Jiang, S., & Cao, Z. (2010) · Advanced Materials · doi:10.1002/adma.200901407 · Cited by 2,027 · cited 4×
“Synthetic zwitterionic materials such as poly(carboxybetaine) (pCB) and poly(sulfobetaine) (pSB) (Figure 7) have been proposed as PEG alternatives due to their strong hydration, conferring high resistance to nonspecific protein fouling in addition to their inherently low immunogenicity [77,78].”
BackgroundInfluentialChemistry for peptide and protein PEGylation
Roberts, M. J., Bentley, M. D., & Harris, J. M. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00022-4 · Cited by 1,604
Polyethylene glycol (PEG): A versatile polymer for pharmaceutical applications
D’souza, A. A., & Shegokar, R. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1182485 · Cited by 1,282
The Impact of PEGylation on Biological Therapies
Veronese, F. M., & Mero, A. (2008) · BioDrugs · doi:10.2165/00063030-200822050-00004 · Cited by 1,034
Turecek, P. L., Bossard, M. J., Schoetens, F., & Ivens, I. A. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.015 · Cited by 733
The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage
Abu Lila, A. S., Kiwada, H., & Ishida, T. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.07.026 · Cited by 721
Bertrand, N., Grenier, P., Mahmoudi, M., Lima, E. M., Appel, E. A., Dormont, F., Lim, J.-M., Karnik, R., Langer, R., & Farokhzad, O. C. (2017) · Nature Communications · doi:10.1038/s41467-017-00600-w · Cited by 708 · cited 3×
“When considering continuously increasing PEG density, it was shown that high PEG densities did not significantly impact NP clearance from circulation [59], though discussion of the relationship between clearance and anti-PEG IgM production, as a known causative factor of ABC, was omitted [37].”
BackgroundAnti-PEG antibodies in the clinic: Current issues and beyond PEGylation
Zhang, P., Sun, F., Liu, S., & Jiang, S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.040 · Cited by 688 · cited 11×
“Other synthetic polymers such as poly(glycerols) (PGs), poly(oxazolines) (POX), poly(hydroxypropyl methacrylate) (PHPMA), poly(2-hydroxyethyl methacrylate) (PHEMA) [71], poly(N-(2-hydroxypropyl) methacrylamide) (HPMA), poly(vinylpyrrolidone) (PVP), poly(N,N-dimethyl acrylamide) (PDMA), and poly(Nacryloylmorpholine) (P…”
BackgroundResultInfluentialXia, Q., Zhang, Y., Li, Z., Hou, X., & Feng, N. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.01.011 · Cited by 665
FDA-approved poly(ethylene glycol)–protein conjugate drugs
Alconcel, S. N. S., Baas, A. S., & Maynard, H. D. (2011) · Polymer Chemistry · doi:10.1039/c1py00034a · Cited by 643
Dams, E. T. M., Laverman, P., Oyen, W. J. G., Storm, G., Scherphof, G. L., van der Meer, J. W. M., Corstens, F. H. M., & Boerman, O. C. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35391-1 · Cited by 607 · cited 1×
“PEGylated liposomes have demonstrated rapid clearance in rat, guinea pig, minipig and beagle dog models after each consecutive dose following their second administration [33,49,50].”
BackgroundAnti‐ PEG immunity: emergence, characteristics, and unaddressed questions
Yang, Q., & Lai, S. K. (2015) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1339 · Cited by 593 · cited 2×
“reported that more than 25% of healthy blood donors exhibited anti-PEG antibodies [38,52], and, in 2016, Yang et al.”
BackgroundPEGylated liposomes: immunological responses
Mohamed, M., Abu Lila, A. S., Shimizu, T., Alaaeldin, E., Hussein, A., Sarhan, H. A., Szebeni, J., & Ishida, T. (2019) · Science and Technology of Advanced Materials · doi:10.1080/14686996.2019.1627174 · Cited by 523 · cited 6×
“As illustrated in a study that utilized PG-modified liposomes, this phenomenon could be explained by the steric hindrance of PG molecules at their surface: This limits the interfacing of PG-liposomes and immunoglobulins on splenic B cells, preventing their stimulation and subsequent generation of anti-polymer antibodi…”
BackgroundInfluentialThe Pharmacology of PEGylation: Balancing PD with PK to Generate Novel Therapeutics
Fishburn, C. S. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21278 · Cited by 474
PEGylation for enhancing nanoparticle diffusion in mucus
Huckaby, J. T., & Lai, S. K. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.08.010 · Cited by 461 · cited 2×
“Additionally, the flexible hydrophilic PEG chains could allow PEG-modified NPs to quickly diffuse through mucin fibers for the effective local release of drugs [9,28].”
BackgroundResultPoly(2-oxazoline)s based biomaterials: a comprehensive and critical update
Lorson, T., Lübtow, M. M., Wegener, E., Haider, M. S., Borova, S., Nahm, D., Jordan, R., Sokolski-Papkov, M., Kabanov, A. V., & Luxenhofer, R. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.05.022 · Cited by 391
PEGylation in anti-cancer therapy: An overview
Mishra, P., Nayak, B., & Dey, R. K. (2016) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2015.08.011 · Cited by 382 · cited 1×
“Few candidates, however, have progressed from the benchtop to the market [23,24], with factors such as a limited in vivo stability and undesirable off-target effects likely contributing to a lack of translational success [10].”
BackgroundImmediate‐type hypersensitivity to polyethylene glycols: a review
Wenande, E., & Garvey, L. H. (2016) · Clinical & Experimental Allergy · doi:10.1111/cea.12760 · Cited by 354
Physiologically Based Pharmacokinetic Modeling of Nanoparticles
Li, M., Al-Jamal, K. T., Kostarelos, K., & Reineke, J. (2010) · ACS Nano · doi:10.1021/nn1018818 · Cited by 351 · cited 1×
“This unexpected immunogenic reaction, which causes the rapid clearance and decreased efficacy of therapeutic agents, is defined as the accelerated blood clearance (ABC) phenomenon [41,42].”
BackgroundThe Immunogenicity of Polyethylene Glycol: Facts and Fiction
Schellekens, H., Hennink, W. E., & Brinks, V. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1067-7 · Cited by 340
Chemistry for peptide and protein PEGylation
Roberts, M. J., Bentley, M. D., & Harris, J. M. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.025 · Cited by 334
Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance
Zamboni, W. C., Torchilin, V., Patri, A. K., Hrkach, J., Stern, S., Lee, R., Nel, A., Panaro, N. J., & Grodzinski, P. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2938 · Cited by 275 · cited 1×
“Few candidates, however, have progressed from the benchtop to the market [23,24], with factors such as a limited in vivo stability and undesirable off-target effects likely contributing to a lack of translational success [10].”
BackgroundGanson, N. J., Povsic, T. J., Sullenger, B. A., Alexander, J. H., Zelenkofske, S. L., Sailstad, J. M., Rusconi, C. P., & Hershfield, M. S. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.10.034 · Cited by 273 · cited 2×
“Thus, clinicians should advise that all patients prescribed PEGylated drugs should be examined for the presence of anti-PEG antibodies in order to preserve patient health and safety and maximize the efficacy of the treatment course [44,53].”
BackgroundPotential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics
Verhoef, J. J. F., Carpenter, J. F., Anchordoquy, T. J., & Schellekens, H. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.08.015 · Cited by 267
Yang, W., Zhang, L., Wang, S., White, A. D., & Jiang, S. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.06.036 · Cited by 242 · cited 3×
“Synthetic zwitterionic materials such as poly(carboxybetaine) (pCB) and poly(sulfobetaine) (pSB) (Figure 7) have been proposed as PEG alternatives due to their strong hydration, conferring high resistance to nonspecific protein fouling in addition to their inherently low immunogenicity [77,78].”
BackgroundPolymer-coated long-circulating microparticulate pharmaceuticals
Torchilin, V. P. (1998) · Journal of Microencapsulation · doi:10.3109/02652049809006831 · Cited by 235 · cited 2×
“PEGylation has been shown to improve the in vivo stability of micelles, liposomes, dendrimers, gold nanoshells, quantum dots and polymeric NPs, thus providing more effective therapeutic action [7,25].”
BackgroundHussain, Z., Khan, S., Imran, M., Sohail, M., Shah, S. W. A., & de Matas, M. (2019) · Drug Delivery and Translational Research · doi:10.1007/s13346-019-00631-4 · Cited by 220 · cited 1×
“Consequently, surface PEG density and molecular weight are two critical factors to be optimized to ensure a minimal PEG-associated immune response [64].”
BackgroundBeyond PEGylation: Alternative surface-modification of nanoparticles with mucus-inert biomaterials
Khutoryanskiy, V. V. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.015 · Cited by 214
Mima, Y., Hashimoto, Y., Shimizu, T., Kiwada, H., & Ishida, T. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00144 · Cited by 209 · cited 1×
“Taken together, the lower levels of plasma IgM resulted in the mitigation of PEG-associated ABC by 28 days post initial pLT administration—indicating that the generation of anti-PEG IgM after the first pLT dose was directly proportional to the magnitude of PEG-associated ABC and supporting the conclusions of additiona…”
ResultToxicity and immunogenicity concerns related to PEGylated-micelle carrier systems: a review
Shiraishi, K., & Yokoyama, M. (2019) · Science and Technology of Advanced Materials · doi:10.1080/14686996.2019.1590126 · Cited by 208 · cited 2×
“When considering continuously increasing PEG density, it was shown that high PEG densities did not significantly impact NP clearance from circulation [59], though discussion of the relationship between clearance and anti-PEG IgM production, as a known causative factor of ABC, was omitted [37].”
BackgroundPEGylated graphene oxide elicits strong immunological responses despite surface passivation
Luo, N., Weber, J. K., Wang, S., Luan, B., Yue, H., Xi, X., Du, J., Yang, Z., Wei, W., Zhou, R., et al. (2017) · Nature Communications · doi:10.1038/ncomms14537 · Cited by 197
Accelerated Blood Clearance Phenomenon Upon Repeated Injection of PEG-modified PLA-nanoparticles
Ishihara, T., Takeda, M., Sakamoto, H., Kimoto, A., Kobayashi, C., Takasaki, N., Yuki, K., Tanaka, K.-I., Takenaga, M., Igarashi, R., et al. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9943-x · Cited by 195 · cited 1×
“reported no apparent relationship between PEG content and the ABC phenomenon [61].”
BackgroundAn influenza virus-inspired polymer system for the timed release of siRNA
Truong, N. P., Gu, W., Prasadam, I., Jia, Z., Crawford, R., Xiao, Y., & Monteiro, M. J. (2013) · Nature Communications · doi:10.1038/ncomms2905 · Cited by 181
Self-citationTruong, N. P., Dussert, M. V., Whittaker, M. R., Quinn, J. F., & Davis, T. P. (2015) · Polymer Chemistry · doi:10.1039/c5py00166h · Cited by 176 · cited 1×
“The synthesized POEGMA had a 3D hyperbranched structure with many side chains of oligoethylene glycol (EG) moieties [69,70] and possessed effective stealth properties.”
BackgroundSelf-citationOu, H., Cheng, T., Zhang, Y., Liu, J., Ding, Y., Zhen, J., Shen, W., Xu, Y., Yang, W., Niu, P., et al. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.10.034 · Cited by 169
Anti-PEG IgM Response against PEGylated Liposomes in Mice and Rats
Ichihara, M., Shimizu, T., Imoto, A., Hashiguchi, Y., Uehara, Y., Ishida, T., & Kiwada, H. (2010) · Pharmaceutics · doi:10.3390/pharmaceutics3010001 · Cited by 168 · cited 4×
“Mice were treated with PEGylated liposomes of 1 μmol/kg, and the production of anti-PEG IgM in mouse sera was determined as a function of time (b) [58].”
BackgroundMethodInfluentialKhor, S. Y., Quinn, J. F., Whittaker, M. R., Truong, N. P., & Davis, T. P. (2019) · Macromolecular Rapid Communications · doi:10.1002/marc.201800438 · Cited by 162
Self-citationA pH-responsive nanoparticle targets the neurokinin 1 receptor in endosomes to prevent chronic pain
Ramírez-García, P. D., Retamal, J. S., Shenoy, P., Imlach, W., Sykes, M., Truong, N., Constandil, L., Pelissier, T., Nowell, C. J., Khor, S. Y., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0568-x · Cited by 159
Self-citationAnti-cancer PEG-enzymes: 30 years old, but still a current approach
Pasut, G., Sergi, M., & Veronese, F. M. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.04.018 · Cited by 152
Baker, D. P., Lin, E. Y.-S., Lin, K., Pellegrini, M., Petter, R. C., Chen, L. L., Arduini, R. M., Brickelmaier, M., Wen, D., Hess, D. M., et al. (2005) · Bioconjugate Chemistry · doi:10.1021/bc050237q · Cited by 144 · cited 1×
“PEGylation has been shown to improve the in vivo stability of micelles, liposomes, dendrimers, gold nanoshells, quantum dots and polymeric NPs, thus providing more effective therapeutic action [7,25].”
BackgroundTaking tissue adhesives to the future: from traditional synthetic to new biomimetic approaches
Bré, L. P., Zheng, Y., Pêgo, A. P., & Wang, W. (2012) · Biomaterials Science · doi:10.1039/c2bm00121g · Cited by 126
Bioinspired Shielding Strategies for Nanoparticle Drug Delivery Applications
Gulati, N. M., Stewart, P. L., & Steinmetz, N. F. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00292 · Cited by 126
Understanding the Role of Anti-PEG Antibodies in the Complement Activation by Doxil in Vitro
Neun, B. W., Barenholz, Y., Szebeni, J., & Dobrovolskaia, M. A. (2018) · Molecules · doi:10.3390/molecules23071700 · Cited by 122 · cited 3×
“Several clinical studies have reported that anti-PEG IgM could be even detected in healthy patients without prior exposure to PEGylated drugs [43,44].”
BackgroundKağa, S., Truong, N. P., Esser, L., Senyschyn, D., Sanyal, A., Sanyal, R., Quinn, J. F., Davis, T. P., Kaminskas, L. M., & Whittaker, M. R. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.7b00995 · Cited by 119
Self-citationHsieh, Y.-C., Wang, H.-E., Lin, W.-W., Roffler, S. R., Cheng, T.-C., Su, Y.-C., Li, J.-J., Chen, C., Huang, C.-H., Chen, B., et al. (2018) · Theranostics · doi:10.7150/thno.22164 · Cited by 116 · cited 1×
“Consequently, many patients have previously been exposed to PEG, resulting in the detection of anti-PEG antibodies in human blood prior to the administration of PEGylated drugs/NPs (Figure 2b,c) [44,53,54].”
BackgroundTa, H. T., Truong, N. P., Whittaker, A. K., Davis, T. P., & Peter, K. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2017.1316262 · Cited by 105 · cited 1×
“Among the aforementioned synthetic polymers, PG, PVP, and PHPMA have been considered as the most promising alternatives to PEG [20].”
BackgroundSelf-citationAnti-PEG Antibodies Inhibit the Anticoagulant Activity of PEGylated Aptamers
Moreno, A., Pitoc, G. A., Ganson, N. J., Layzer, J. M., Hershfield, M. S., Tarantal, A. F., & Sullenger, B. A. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.02.001 · Cited by 103 · cited 2×
“reported that the prevalence of anti-PEG antibodies in untreated patients was up to 70% [51].”
BackgroundPolypeptides with High Zwitterion Density for Safe and Effective Therapeutics
Zhang, P., Jain, P. R., Tsao, C., Yuan, Z., Li, W., Li, B., Wu, K., Hung, H., Lin, X., & Jiang, S. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201802452 · Cited by 99 · cited 3×
“interrogated an alternative stealth material consisting of polypeptides with a high zwitterion density (PepCB) (Figure 8a) by utilizing uricase as a model protein to examine the different pharmacokinetic and immunological profiles of uricase-modified PepCB and PEGylated uricase in rats in vivo [79].”
BackgroundMethodInfluentialJoh, D. Y., Zimmers, Z. A., Avlani, M., Heggestad, J. T., Aydın, H. B., Ganson, N. J., Kumar, S., Fontes, C. M., Achar, R. K., Hershfield, M. S., et al. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801177 · Cited by 96 · cited 8×
“modified PEG into a bottlebrush architecture to overcome PEG-associated ABC [67], thus presenting POEGMA as an alternative to linear PEG.”
BackgroundInfluentialShimizu, T., Lila, A. S. A., Fujita, R., Awata, M., Kawanishi, M., Hashimoto, Y., Okuhira, K., Ishima, Y., & Ishida, T. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.02.019 · Cited by 95 · cited 4×
“Used with permission from the European Journal of Pharmaceutics and Biopharmaceutics [65].”
BackgroundMethodInfluentialImmunological Properties of Uricase Conjugated to Neutral Soluble Polymers
Caliceti, P., Schiavon, O., & Veronese, F. M. (2001) · Bioconjugate Chemistry · doi:10.1021/bc000119x · Cited by 90 · cited 2×
“They found that low levels of anti-PEG IgM were generated after the second immunization of PEGylated uricase [48].”
BackgroundStealth coatings for nanoparticles
Hadjesfandiari, N., & Anilkumar, P. (2018) · Elsevier eBooks · doi:10.1016/b978-0-08-101750-0.00013-1 · Cited by 90
Deng, Y., Zhao, Wang, Yan, Y., Ma, Zang, & She (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s30943 · Cited by 87 · cited 5×
“By varying PEG surface densities, the circulation time of PEGylated lipid nanoparticles after the initial dose can be tuned, consequently eliciting control over PEG-associated ABC [60].”
BackgroundInfluentialPre-existing antibody: biotherapeutic modality-based review
Gorovits, B., Clements-Egan, A., Birchler, M., Liang, M., Myler, H., Peng, K., Purushothama, S., Rajadhyaksha, M., Salazar-Fontana, L., Sung, C., et al. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9878-1 · Cited by 85
Truong, N. P., Whittaker, M. R., Anastasaki, A., Haddleton, D. M., Quinn, J. F., & Davis, T. P. (2015) · Polymer Chemistry · doi:10.1039/c5py01467k · Cited by 81
Self-citationArmstrong, J. K. (2009) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8679-5_9 · Cited by 81 · cited 4×
“3% of allergic patients contained anti-PEG antibodies [52].”
BackgroundInfluentialKhor, S. Y., Vu, M. N., Pilkington, E. H., Johnston, A. P. R., Whittaker, M. R., Quinn, J. F., Truong, N. P., & Davis, T. P. (2018) · Small · doi:10.1002/smll.201801702 · Cited by 81
Self-citationNanoparticle-macrophage interactions: A balance between clearance and cell-specific targeting
Rattan, R., Bhattacharjee, S., Zong, H., Swain, C., Siddiqui, M. A., Visovatti, S., Kanthi, Y. M., Desai, S., Pinsky, D. J., & Goonewardena, S. N. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.06.040 · Cited by 75 · cited 1×
“By considering NP PEGylation within the context of current biomedical approaches, it was concluded, in accordance with other research, that functionalization with PEG could improve the systemic delivery of NPs [9,29].”
ResultSurfactant-free RAFT emulsion polymerization using a novel biocompatible thermoresponsive polymer
Truong, N. P., Quinn, J. F., Anastasaki, A., Rolland, M., Vu, M. N., Haddleton, D. M., Whittaker, M. R., & Davis, T. P. (2017) · Polymer Chemistry · doi:10.1039/c6py02158a · Cited by 66 · cited 1×
“The synthesized POEGMA had a 3D hyperbranched structure with many side chains of oligoethylene glycol (EG) moieties [69,70] and possessed effective stealth properties.”
BackgroundSelf-citationPEGylation of therapeutic oligonucletides: From linear to highly branched PEG architectures
Lu, X., & Zhang, K. (2018) · Nano Research · doi:10.1007/s12274-018-2131-8 · Cited by 63
Zwitterlation mitigates protein bioactivity loss in vitro over PEGylation
Han, Y., Yuan, Z., Zhang, P., & Jiang, S. (2018) · Chemical Science · doi:10.1039/c8sc01777h · Cited by 52 · cited 2×
“A prolonged circulation time and a reduced ABC was observed after repeated injections of zwitterlated interferon alpha-2a compared to the PEGylated agent, and, importantly, zwitterlation could mitigate interferon alpha-2a bioactivity loss in vitro over PEGylated interferon alpha-2a [63].”
BackgroundLi, C., Zhao, X., Wang, Y., Yang, H., Li, H., Li, H., Tian, W., Yang, J., & Cui, J. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.01.012 · Cited by 48 · cited 2×
“As has been previously described, the production of anti-PEG IgM following an initial dose of PEGylated drugs/NPs is causative of the ABC phenomenon [55].”
BackgroundComplement Activation by PEGylated Gold Nanoparticles
Quach, H. Q., Kong, R. L. X., & Kah, J. C. Y. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00793 · Cited by 47 · cited 1×
“This phenomenon can be explained by an increased NP hydrophilicity that was correlated with increasing PEG MW, consequently decreasing the absorption of complement proteins and thus limiting the activation of the complement system [62].”
BackgroundCarbohydrate PEGylation, an approach to improve pharmacological potency
Giorgi, M. E., Agusti, R., & de Lederkremer, R. M. (2014) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.10.147 · Cited by 44
Sebak, A. A. (2018) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2018v10i5.27568 · Cited by 42 · cited 2×
“The administration of PEGylated drugs can lead to the production of anti-PEG antibodies (anti-PEG immunoglobulin M (IgM)) and immune response (Figure 1) [30].”
BackgroundTruong, N. P., Zhang, C., Nguyen, T. A. H., Anastasaki, A., Schulze, M. W., Quinn, J. F., Whittaker, A. K., Hawker, C. J., Whittaker, M. R., & Davis, T. P. (2018) · ACS Macro Letters · doi:10.1021/acsmacrolett.7b00978 · Cited by 39
Self-citationWang, F., Ye, X., Wu, Y., Wang, H., Sheng, C., Peng, D., & Chen, W. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.10.027 · Cited by 36 · cited 3×
“fabricated PEGylated liposomal gambogenic acid (PEG-GEA-L; 2 kDa) in order to evaluate the contribution of anti-PEG IgM to ABC via repeated intravenous injection of PEGylated liposomes in rat models [57].”
BackgroundInfluentialWang, C., Cheng, X., Sui, Y., Luo, X., Jiang, G., Wang, Y., Huang, Z., She, Z., & Deng, Y. (2013) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2013.10.002 · Cited by 27 · cited 4×
“Used with permission from the European Journal of Pharmaceutics and Biopharmaceutics [65].”
BackgroundMethodResultInfluentialPEGylation and anti-PEG antibodies
Lila, A. S. A., Shimizu, T., & Ishida, T. (2018) · Elsevier eBooks · doi:10.1016/b978-0-08-101750-0.00003-9 · Cited by 27 · cited 4×
“The authors utilized PEGylated ovalbumin (OVA), bovine superoxide dismutase (SOD) and pollen extract, demonstrating that anti-PEG IgM production occurred after the injection of the PEGylated OVA while the free OVA and SOD did not induce immune activation [33].”
BackgroundMethodInfluentialEffect of Kupffer cells depletion on ABC phenomenon induced by Kupffer cells-targeted liposomes
Lai, C., Li, C., Liu, M., Qiu, Q., Luo, X., Liu, X., Hu, L., Deng, Y., & Song, Y. (2018) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2018.07.004 · Cited by 24 · cited 1×
“Kupffer cells are a type of antigen-presenting cell (APC) that act as a bridge between the innate and adaptive immune systems, and they have been shown to clear PEGylated liposomes from the body after their detection with anti-PEG antibodies [46].”
BackgroundImpact of anti-PEG antibodies on PEGylated nanoparticles fate in vivo
Park, K. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.09.014 · Cited by 20 · cited 1×
“Several clinical studies have reported that anti-PEG IgM could be even detected in healthy patients without prior exposure to PEGylated drugs [43,44].”
BackgroundSelf-citationAnti-PEG IgM Production via a PEGylated Nano-Carrier System for Nucleic Acid Delivery
Ichihara, M., Moriyoshi, N., Lila, A. S. A., Ishida, T., & Kiwada, H. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-140-0_4 · Cited by 19
Nunvářová, K., Charvátová, B., Šlouf, M., Hermanová, S., & Merna, J. (2019) · European Polymer Journal · doi:10.1016/j.eurpolymj.2019.03.029 · Cited by 19 · cited 3×
“Other synthetic polymers such as poly(glycerols) (PGs), poly(oxazolines) (POX), poly(hydroxypropyl methacrylate) (PHPMA), poly(2-hydroxyethyl methacrylate) (PHEMA) [71], poly(N-(2-hydroxypropyl) methacrylamide) (HPMA), poly(vinylpyrrolidone) (PVP), poly(N,N-dimethyl acrylamide) (PDMA), and poly(Nacryloylmorpholine) (P…”
BackgroundAnti-PEG IgM Production via a PEGylated Nanocarrier System for Nucleic Acid Delivery
Lila, A. S. A., & Ishida, T. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9092-4_22 · Cited by 16
Qi, F., Qi, J., Hu, C., Shen, L., Yu, W., & Hu, T. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.03.046 · Cited by 10 · cited 5×
“Qi et al. utilized a low MW PEG (2 or 5 kDa) that lacked a methoxyl moiety as a linker to conjugate arabinogalactan (AG) to staphylokinase (SAK) [68] in order to enhance SAK efficacy through a reduction of immunogenicity, improved half-life and stabilized bioactivity.”
BackgroundMethodInfluentialMukhopadhyay, S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814031-4.00018-0 · Cited by 5
Research works printed but not linked: 4
- Mohapatra, S.S., Ranjan, S., Dasgupta, N., Mishra, R.K., and Thomas, S. (2019). Nano drugs: A critical review of their patents and market. Characterization and Biology of Nanomaterials for Drug Delivery: Nanoscience and Nanotechnology in Drug Delivery, Elsevier Ltd.
- Pasut, G., and Zalipsky, S. (2020). 5-Immunological responses to PEGylated proteins: Anti-PEG antibodies. Polymer-Protein Conjugates, Elsevier.
- Roitt, I., and Delves, P. (1998). Hapten. Encyclopedia of Immunology, Elsevier Ltd.. [2nd ed.].
- Parambath, A. (2018). PEGylation and its alternatives: A summary. Engineering of Biomaterials for Drug Delivery Systems: Beyond Polyethylene Glycol, Elsevier Ltd.
Cited by
Polymeric Nanoparticles for Drug Delivery
Beach, M. A., Nayanathara, U., Gao, Y., Zhang, C., Xiong, Y., Wang, Y., & Such, G. K. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00705 · Cited by 1,155
Lombardo, D., & Kiselev, M. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030543 · Cited by 718
Kozma, G. T., Shimizu, T., Ishida, T., & Szebeni, J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.024 · Cited by 696
Biodegradable Polymeric Nanoparticles for Drug Delivery to Solid Tumors
Gagliardi, A., Giuliano, E., Venkateswararao, E., Fresta, M., Bulotta, S., Awasthi, V., & Cosco, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.601626 · Cited by 571
Molecularly Imprinted Polymers: Antibody Mimics for Bioimaging and Therapy
Haupt, K., Medina Rangel, P. X., & Bui, B. T. S. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00428 · Cited by 561
Metadata
- Authors
- Hoang Thi, T. T., Pilkington, E. H., Nguyen, D. H., Lee, J. S., Park, K. D., & Truong, N. P.
- Affiliations
- Biomaterials and Nanotechnology Research Group, Faculty of Applied Sciences, Ton Duc Thang University, Ho Chi Minh City 758307, Vietnam
- Monash University (AU)
- Graduate University of Science and Technology (VN)
- Yale University (US)
- Ajou University (KR)
- Corresponding author
- Truong, Nghia P.
- ORCID
- Venue
- Polymers
- Publisher
- MDPI AG
- Published
- 2020-02-02
- Volume
- 12
- Issue
- 2
- Pages
- 298
- ISSN
- 2073-4360 (ISSN-L)
- PMC
- PMC7077443
- OpenAlex
- W3003603323
- Cited by
- 668
- References
- 79
- Citations by year
- 2026: 63 · 2025: 106 · 2024: 117 · 2023: 126 · 2022: 118 · 2021: 85 · 2020: 53
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Polymers (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Monash University Research Portal (Monash University) (submittedVersion, cc-by)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Australian Research Council (DE180100076, DP200100231)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
- Keywords
- polyethylene glycol, anti-PEG antibodies, PEGylation, PEG alternatives, drug delivery, bioconjugation, nanomedicine, blood circulation time, hypersensitivity, siRNA, microRNA, oligonucleotides, nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.